Patent · US Active

Antigenic GM-CSF peptides and antibodies to GM-CSF

US9422367B2 · kind B2 · utility

0Cited by
20References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 26, 2013
Grant dateAug 23, 2016
Priority date
Expiry dateNov 30, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.